Release Date: February 28, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

IMI PLC (IMIAF) reported a strong financial performance in 2024, with 4% organic sales growth and 10% organic adjusted operating profit growth. The company increased its adjusted operating margins by 100 basis points to 19.7% and set a new medium-term margin target of 20% plus. IMI PLC (IMIAF) announced a 10% increase in the final dividend and a 200 million pounds share buyback program, reflecting confidence in future performance. The company expects to generate over a billion pounds in free cash flow over the next three years, indicating strong cash generation capabilities. IMI PLC (IMIAF) successfully managed a cyber incident, returning to normal operations swiftly and enhancing IT security measures.

Negative Points

The company faced foreign exchange and tax rate headwinds, which impacted adjusted basic EPS growth, limiting it to 5% higher than 2023. Restructuring costs were higher than initially estimated, totaling 48 million pounds in 2024, which affected overall financial performance. The life sciences sector experienced a 2% decline in organic revenue, with no forecasted recovery in the near term. Industrial automation saw a 3% decline in organic revenue due to softer markets in Europe and the Americas. The company anticipates a one-off exceptional charge of 20 to 25 million pounds in 2025 related to IT systems recovery and infrastructure upgrades following the cyber incident.

Q & A Highlights

Warning! GuruFocus has detected 6 Warning Sign with IMIAF.

Q: Can you provide insights into the process automation order book and its impact on 2025 growth? A: The process automation order book increased by nearly 100 million pounds last year, with a book-to-bill ratio of 1.12%. This includes a significant marine order that will be shipped over several years. The strong order book underpins growth for 2025, and we expect continued robust growth from process automation. - Respondent: CEO

Q: Are there any significant new platform launches in life sciences, and how do you view inventory dynamics? A: We have secured several future platforms in analytical and medical devices, but we are not predicting a recovery in the life sciences market. The sector represents 7% of our business, and while there is increased use of reagents, we anticipate a flat year for life sciences. - Respondent: CEO

Q: Can you explain the strong growth in climate control despite weaknesses in the residential sector? A: The growth was primarily driven by geographic factors, particularly in Germany, due to new standards and regulations around energy savings. Our business focuses on energy-efficient products, and the majority of our sales are in Europe, where energy-saving regulations are stringent. - Respondent: CEO

Story Continues

Q: What is the outlook for industrial automation, and how is the Growth Hub contributing to margin targets? A: The 60-day moving average for industrial automation orders is slightly negative, impacted by the cyber event. However, the Growth Hub is driving margin accretive projects across various sectors, contributing to our confidence in achieving margins above 20% in the medium term. - Respondent: CEO

Q: How does the M&A landscape look, and what is your approach to acquisitions? A: The M&A pipeline is robust, with a focus on private companies that can enhance our core business. We maintain strict discipline on pricing and return on invested capital. Our strategy is to acquire businesses that align with our growth markets and provide strong financial returns. - Respondent: CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments